Literature DB >> 18520327

Autoimmune hemolytic anemia and common variable immunodeficiency: a case-control study of 18 patients.

Pascal Sève1, Laure Bourdillon, Francoise Sarrot-Reynauld, Marc Ruivard, Rolland Jaussaud, Damien Bouhour, Bernard Bonotte, Martine Gardembas, Vincent Poindron, Marie-France Thiercelin, Christiane Broussolle, Eric Oksenhendler.   

Abstract

To describe the main characteristics and treatment of autoimmune hemolytic anemia (AHA) in patients with common variable immunodeficiency (CVID), we analyzed data from 18 patients, 4 from an earlier study and 14 from the French DEF-I cohort on adult patients with primary hypogammaglobulinemia. To be included, patients had to have CVID and a previous history of AHA with a hemoglobin level < or =90 g/L at onset. To determine whether AHA is associated with a particular clinical phenotype of CVID, we conducted a case-control study from the DEF-I cohort. The estimated frequency of AHA in CVID patients from the DEF-I cohort was 5.5% (14/252). Median age at AHA diagnosis was 26 years (range, 1-57 yr), and 27.5 years (range, 5-61 yr) at CVID diagnosis. CVID was diagnosed before the onset of AHA in only 2 patients (11%). CVID was diagnosed more than 6 months after AHA in 10 cases (55.5%), and the 2 conditions were diagnosed concomitantly in 6 cases. The 14 patients included in the DEF-I cohort were compared with 238 control patients with CVID but without AHA. Corticosteroids were used as initial treatment for all patients in the current study. An initial response was obtained in 15 of 18 (83%) patients. Overall, 9 of these (60%) achieved a lasting response with steroids alone (7 patients) or in combination with intravenous immunoglobulin (2 patients). Seven patients underwent splenectomy, and 5 additional splenectomies were performed for associated autoimmune thrombocytopenic purpura. After splenectomy, a lasting response was obtained in 3 of the 7 patients with AHA. However, 5 of the 12 splenectomized patients experienced life-threatening infection. Severe infection occurred in 2 of 4 patients receiving immunosuppressive drugs. At the end of follow-up, 13 of 18 (72%) patients were in treatment-free remission (13 complete responses), and 4 of 18 (22%) were in remission while on prednisone < or =20 mg/d. One patient had died, of cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18520327     DOI: 10.1097/MD.0b013e31817a90ba

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  13 in total

1.  International Consensus Document (ICON): Common Variable Immunodeficiency Disorders.

Authors:  Francisco A Bonilla; Isil Barlan; Helen Chapel; Beatriz T Costa-Carvalho; Charlotte Cunningham-Rundles; M Teresa de la Morena; Francisco J Espinosa-Rosales; Lennart Hammarström; Shigeaki Nonoyama; Isabella Quinti; John M Routes; Mimi L K Tang; Klaus Warnatz
Journal:  J Allergy Clin Immunol Pract       Date:  2015-11-07

Review 2.  How I treat common variable immune deficiency.

Authors:  Charlotte Cunningham-Rundles
Journal:  Blood       Date:  2010-03-23       Impact factor: 22.113

3.  Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment.

Authors:  Quentin A Hill; Anita Hill; Sigbjørn Berentsen
Journal:  Blood Adv       Date:  2019-06-25

4.  Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients.

Authors:  Delphine Gobert; James B Bussel; Charlotte Cunningham-Rundles; Lionel Galicier; Agnès Dechartres; Alice Berezne; Bernard Bonnotte; Thierry DeRevel; Christophe Auzary; Roland Jaussaud; Claire Larroche; Alain LeQuellec; Marc Ruivard; Pascal Seve; Amar Smail; Jean-François Viallard; Bertrand Godeau; Olivier Hermine; Marc Michel
Journal:  Br J Haematol       Date:  2011-10-08       Impact factor: 6.998

5.  Common variable immunodeficiency.

Authors:  Jonathan S Tam; John M Routes
Journal:  Am J Rhinol Allergy       Date:  2013 Jul-Aug       Impact factor: 2.467

Review 6.  Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies.

Authors:  Jolan E Walter; Jocelyn R Farmer; Zsofia Foldvari; Troy R Torgerson; Megan A Cooper
Journal:  J Allergy Clin Immunol Pract       Date:  2016 Nov - Dec

7.  Outcomes of splenectomy in patients with common variable immunodeficiency (CVID): a survey of 45 patients.

Authors:  G K Wong; S Goldacker; C Winterhalter; B Grimbacher; H Chapel; M Lucas; D Alecsandru; D McEwen; I Quinti; H Martini; C Milito; R E Schmidt; D Ernst; T Espanol; A Vidaller; J Carbone; E Fernandez-Cruz; V Lougaris; A Plebani; N Kutukculer; L I Gonzalez-Granado; R Contreras; S Kiani-Alikhan; M A A Ibrahim; J Litzman; A Jones; H B Gaspar; L Hammarstrom; U Baumann; K Warnatz; A P Huissoon
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

Review 8.  Refractory autoimmune hemolytic anemia in a patient with DiGeorge syndrome treated successfully with plasma exchange: a case report and review of the literature.

Authors:  Moussab Damlaj; Chantal Séguin
Journal:  Int J Hematol       Date:  2014-07-31       Impact factor: 2.490

9.  Pathogenesis of autoimmunity in common variable immunodeficiency.

Authors:  Klaus Warnatz; Reinhard E Voll
Journal:  Front Immunol       Date:  2012-07-18       Impact factor: 7.561

Review 10.  Common variable immunodeficiency: an update.

Authors:  Ulrich Salzer; Klaus Warnatz; Hans Hartmut Peter
Journal:  Arthritis Res Ther       Date:  2012-09-24       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.